An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)

BACKGROUND: Nivolumab has been approved in China as second-line treatment for advanced non-small-cell lung cancer (NSCLC) via weight-based infusion, based on the CheckMate 078 study. We investigated the safety and efficacy of 240 mg flat-dose nivolumab in patients with advanced NSCLC, including thos...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shun, Cheng, Ying, Zhou, Jianying, Wang, Mengzhao, Zhao, Jun, Wang, Baocheng, Chen, Gongyan, Feng, Jifeng, Ma, Zhiyong, Wu, Lin, Wang, Changli, Ma, Kewei, Zhang, Shucai, Liang, Jun, Song, Yong, Wang, Jie, Wu, Yi-Long, Li, Ang, Huang, Yizhi, Chang, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679349/
https://www.ncbi.nlm.nih.gov/pubmed/36425873
http://dx.doi.org/10.1177/17588359221138380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679349/
https://www.ncbi.nlm.nih.gov/pubmed/36425873
http://dx.doi.org/10.1177/17588359221138380

Ejemplares similares